Retrospective Study on the Incidence and Management of Anemia in Oncology
RESPIRE
1 other identifier
observational
349
1 country
1
Brief Summary
The incidence of anemia ranges from 20 to 75% depending on the type of cancer. It is often present at diagnosis and increases with specific treatments. It has an impact on overall survival and quality of life. Its origins are multiple (pure iron deficiency or functional, malnutrition, dyserythropoiesis, insufficiency renal, hemolysis, chemotherapy, radiotherapy, targeted therapies). Transfusion is the most common treatment offered in the management of anemia. The incidence of anemia and its consequences are often underestimated during cancer management. Recommendations were published in 2012. An inventory of the incidence of anemia before and after the publication of these recommendations are proposed in order to assess their impact on daily practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 20, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 20, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
January 20, 2021
CompletedFirst Submitted
Initial submission to the registry
February 26, 2021
CompletedFirst Posted
Study publicly available on registry
March 3, 2021
CompletedMarch 3, 2021
February 1, 2021
8 months
February 26, 2021
February 26, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Incidence of anemia
number of patient with anemia (\<11.0 g/dL) upon admission to hospital on the number of patients hospitalized over the period
2 years
Secondary Outcomes (5)
Assessment of transfusion prescriptions
2 years
Assessment of erythropoiesis stimulating agents (EPO) prescriptions
2 years
Assessment of iron prescriptions
2 years
Time between last transfusion and date of death
2 years
overall survival
2 years
Study Arms (2)
period 2011
period 2018
Interventions
Eligibility Criteria
Adult patients with cancer and justifying continuous hospitalization for more than one night regardless of pattern. Patient informed and not having expressed opposition to the study.
You may qualify if:
- Age ≥ 18 years old,
- Follow-up for cancer justifying hospitalization,
- Presenting anemia defined by a hemoglobin level \<11 g / dL,
- Patient not having objected to the collection of his data after oral and written information.
You may not qualify if:
- patients with a hemoglobin level ≥ 11 g / dL,
- adult patients under guardianship, curatorship or deprived of liberty,
- pregnancy or breast-feeding in progress at the time of hospitalization.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Wepromlead
Study Sites (1)
Centre Jean Bernard - Clinique Victor Hugo
Le Mans, 72000, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Katell LE DÛ, MD
Centre Jean Bernard/Clinique Victor Hugo - LE MANS
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 26, 2021
First Posted
March 3, 2021
Study Start
May 20, 2020
Primary Completion
January 20, 2021
Study Completion
January 20, 2021
Last Updated
March 3, 2021
Record last verified: 2021-02
Data Sharing
- IPD Sharing
- Will not share